Perspective Therapeutics and Merck to Test PSV359 With Keytruda in FAP-α Solid Tumors

M&A · PartnershipProduct / Tech
โดย GlobeNewswire·US·Read original
Summary · why it matters

Perspective Therapeutics has signed a clinical trial collaboration and supply agreement with Merck to evaluate its targeted alpha-particle therapy [212Pb]PSV359 in combination with Keytruda, Merck's anti-PD-1 therapy, in patients with FAP-α-positive solid tumors. The combination will be tested under an amendment to Perspective's ongoing Phase 1/2a study of [212Pb]PSV359 in certain types of non-small cell lung cancer and colorectal cancer that express fibroblast activation protein alpha, under clinicaltrials.gov identifier NCT06710756. Perspective is sponsoring the study and Merck is providing pembrolizumab at no cost, with enrollment already completed in the first three monotherapy dose cohorts. Markus Puhlmann, Perspective's Chief Medical Officer, said FAP-α is associated with the majority of solid tumors and a tumor microenvironment historically characterized by poor drug penetration and immune suppression or exclusion, and that combining targeted radiopharmaceutical treatment with a well-established immune checkpoint inhibitor may reshape the tumor environment and improve outcomes for patients with advanced FAP-α-positive solid tumors.

Impact on stocks 3

Biotech & Genomic Medicine▲ · 2 stocks
Perspective Therapeutics Inc.
CATX
▲ PositiveTechnologyrelevance

Perspective signs clinical trial collaboration with Merck to evaluate its [212Pb]PSV359 in combination with Keytruda in FAP-α-positive solid tumors.

Merck & Company Inc
MRK
▲ PositiveTechnologyrelevance

Merck will supply Keytruda (pembrolizumab) at no cost for the combination study, expanding its immuno-oncology combination data.

Critical Materials & Supply Chain▲ · 1 stocks

Theme Impact 2

Related news

▲2

Akeso Wins China Phase I Clearance for AK158D1 Bispecific ADC

Akeso has secured Phase I clinical trial clearance in China for AK158D1, a bispecific antibody drug conjugate targeting EGFR and TROP2 in advanced solid tumors. The clearance puts fresh attention on the company's pipeline as it pushes deeper into IO2.0 and ADC2.0. Akeso's shares recently traded at HK$90.5, up 3.37% over 90 days but down 20.12% year to date, against a consensus analyst price target of HK$158.28, with the most bullish target at HK$226.04 and the most bearish at HK$125.08. The company remains exposed to execution setbacks given its reliance on a handful of key drugs and a current net loss of CN¥967.2 million.
9926.HK ▲
Biotech & Genomic Medicine ▲
Simply Wall St·9hRead more →
▲2

Merck's KEYTRUDA Plus Padcev Wins CHMP Backing for EU Bladder Cancer

Merck received a positive opinion from the European Medicines Agency's CHMP for KEYTRUDA plus Padcev in muscle-invasive bladder cancer. The CHMP backed the combination as perioperative therapy for adults with resectable muscle-invasive bladder cancer in the European Union. If endorsed by the European Commission, the regimen would be the first PD-1 inhibitor plus antibody-drug conjugate option for this setting in Europe. The addressable group in Europe is relatively concentrated but clinically high need, with bladder cancer cases estimated at about 224,700 in 2022, roughly 25% of them classified as muscle invasive. The key near-term marker is the European Commission ruling expected by the fourth quarter of 2026, since the CHMP only issues recommendations.
MRKMRK.XETRA
Biotech & Genomic Medicine ▲
Simply Wall St·11hRead more →
impact 4

FDA Grants Full Approval to Lilly's Inluriyo Plus Verzenio for ESR1-Mutated Breast Cancer

Eli Lilly and Company announced that the U.S. Food and Drug Administration has granted full approval to Inluriyo, or imlunestrant, in combination with Verzenio, or abemaciclib, for adults with ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer whose disease progressed after at least one line of endocrine therapy. The decision rests on the Phase 3 EMBER-3 trial, in which the combination doubled median progression-free survival versus Inluriyo alone, at 11.1 months versus 5.5 months, with a hazard ratio of 0.53 and a 95% confidence interval of 0.35 to 0.80, among the 159 patients with ESR1-mutated metastatic breast cancer. In that trial, 92 patients received Inluriyo alone and 67 received the combination after an aromatase inhibitor, with or without a CDK4/6 inhibitor, in either the adjuvant or metastatic setting. The approval marks the second FDA clearance for Inluriyo in less than a year, following its September 2025 monotherapy approval for the same ER-positive, HER2-negative, ESR1-mutated metastatic population. Inluriyo is also being studied in the Phase 3 EMBER-4 trial in the adjuvant setting for ER-positive, HER2-negative early-stage breast cancer, the largest adjuvant oral SERD trial with more than 8,000 patients enrolled across 650-plus sites in more than 30 countries, with initial results anticipated in 2027. The combination is now available in the United States.
LLY ▲
Biotech & Genomic Medicine ▲
PR Newswire·16hRead more →
© 2026 MarketDXNews